18F-DOPA PET-guided proton beam therapy improved overall survival in older glioblastoma patients, with a median OS of 13.1 months and no grade 4 adverse events. The hypofractionated regimen, completed ...
A phase I clinical trial on combined (neo-)adjuvant intravenous plus intracranial administration of ipilimumab and nivolumab in recurrent glioblastoma (NEO-GLITIPNI). This is an ASCO Meeting Abstract ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results